Angiotensin II antagonists

Bibliography

• MACMAHON S, PETO R, CUTLER J e al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 335:765–774.
   PubMed Web of Science ®Google Scholar
• Laragh JH, Brenner BM (Eds.), Raven Press, NY (1995):1763–1790.
   Google Scholar
• ANDERSON GH, STREETEN DHP, DALAKOS TG: Agonistic response of vascular receptors to 1-sar-8-ala-angiotensin II (saralasin). Clin. Res. (1975) 23:218A.
   Google Scholar
• GREENLEE WJ, SIEGL PK: Angiotensin/renin modulators. Ann. Rep. Med. Chem. (1991) 26:63–72.
   Web of Science ®Google Scholar
• GARG R, YUSUF S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J. Am. Med. Assoc. (1995) 273:1450–1456.
   PubMed Web of Science ®Google Scholar
• GANSEVOORT RT, DEZEEUW D, DEEJONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin angiotensin system Kidney Int. (1994) 40:243–250.
   Google Scholar
• BRETZEL RG: Protecting the residual renal function: which drugs of choice Am. J. Hypertens. (1997) 10:1595–1665.
   Google Scholar
• DAHLOF B, DEVEREUX R, DE FAIRE U e al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Rationale, design, and methods. Am. J. Hypertens. (1997) 10:705–712.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS PBMWM, WONG PC, CHIU AT e al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. (1993) 45:205–251.
   PubMed Web of Science ®Google Scholar
• MARKHAM A, GOA KL: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs (1997) 54:299–311.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA K, NAKA T, CHATANI F e al. Candesartan cilexetil: a review of its preclinical pharmacology. J. Human Hypertens. (1997) 11 (Suppl. 2): S9–S17.
   PubMed Web of Science ®Google Scholar
• DE GASPARO M, HUSAIN A, ALEXANDER W, et al.: Proposed update of the angiotensin receptor nomenclature. Hypertension (1995) 25:924–927.
   PubMed Web of Science ®Google Scholar
• SMITH RD, CHIU AT, WONG PC e al. Pharmacology of non-peptide angiotensin II receptor antagonists. Ann. Rev. Pharmacol. Toxicol. (1992) 32:135–165.
   PubMed Web of Science ®Google Scholar
• WOLF G, NEILSON EG: From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Exp. Nephrol. (1996) 4\(Suppl. 1):8–19.
   PubMedGoogle Scholar
• KAMBAYASHI Y, TAKAHASHI K, BARDHAN S e al. Molecular structure and function of angiotensin type 2 receptor. Kidney Int. (1994) 48:1502–1504.
   Web of Science ®Google Scholar
• SMITH RD, TIMMERMANS PBMVVM: Ang II receptor antagonists. Pharm. News (1997) 4:16–20.
   Google Scholar
• ICHIKI T, LABOSKY PA, SHIOTA C e al. Effects on blood pressure and exploratory behavior of mice lacking angiotensin II type 2 receptor. Nature (1995) 377:748–750.
   PubMed Web of Science ®Google Scholar
• NAHMIAS C, STROSBERG AD: The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function. Trends Pharmacol. Sci. (YEAR) 18:223–225.
   PubMed Web of Science ®Google Scholar
• STOLL M, STOECKELINGS UM, PAUL M e al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. (1995) 95:651–657.
   PubMed Web of Science ®Google Scholar
• LIU Y-H, YANG X-P, SHAROV VG, et al. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension (1996) 27:7–13.
   PubMed Web of Science ®Google Scholar
• BURT VL, WHELTON P, ROCCELLA EJ, et al. Prevalence of hypertension in the US adult population. Results from the third National Health and Nutrition Examination Survey, 1988-1992. Hypertension (1995) 25:305–313.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Heart and stroke facts: 1996 statistical supplement. Am. Heart Assoc. (1996) Supplement:1–23.
   PubMed Web of Science ®Google Scholar
• BURRELL LM, JOHNSTON CI: Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs and Aging (1997) 10:421–434.
   PubMed Web of Science ®Google Scholar
• EPSTEIN M: Evolving concepts in the management of hypertension. Clin. Cardiol. (1995) 18(Suppl. III) :111–3–111–11.
   Google Scholar
• HANSSON L: Medical and cost-economy aspects of modern antihypertensive therapy - with special reference to 2 years of clinical experience with losartan. Blood Pressure (1997) 6 (Suppl. 1):52–55.
   PubMedGoogle Scholar
• ITSKOVITZ, HD: Antihypertensive therapy targeted to the needs of the patient: focus on the renin-angiotensin system; older and newer agents. Clin. Cardiol. (1995) 18(Suppl. III):111–23–111–28.
   Google Scholar
• BITTAR N: Maintaining long-term control of blood pressure: the role of improved compliance. Clin. Cardiol. (1995) 18\(Suppl. 111)111-12-111-16.
   PubMedGoogle Scholar
• Wolff M (Ed.), John Wiley & Sons, Inc., New York (1996):265–321.
   Google Scholar
• JOINT NATIONAL COMMITTEE ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD PRESSURE: The sixth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (INC VI). (1997).
   Google Scholar
• Campbell RWF, Francis GS (Eds.), Euromed Communications, USA (1997)75–94.
   Google Scholar
• HOUGHTON AR, COWLEY AJ: Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners Int. J. Cardiol. (1997) 59:7–10.
   Web of Science ®Google Scholar
• ELMFELDT D, GEORGE M, HUBNER R e al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J. Human Hypertens. (1997) 11 (Suppl. 2):S49–S55.
   Google Scholar
• GILLIS JC, MARKHAM A: Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs (1997) 54:885–903.
   PubMed Web of Science ®Google Scholar
• GOA KL, WAGSTAFF AJ: Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs (1996) 51:820–845.
   PubMed Web of Science ®Google Scholar
• PHILIPP T, LETZEL H, ARENS H-J: Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J. Human Hypertens. (1997) 11 (Suppl. 2):S67–S68.
   PubMed Web of Science ®Google Scholar
• GOLDBERG Al, DUNLAY MC, SWEET CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am. J. Cardiol. (1995) 75:793–795.
   PubMed Web of Science ®Google Scholar
• SMITH RD, AURUP P, GOLDBERG Al e al. Long-term safety of losartan in open-label trial in patients with mild to moderate essential hypertension. Am. J. Hypertens. (1998).
   Google Scholar
• HEDNER T, HIMMELMANN A: Results of a 13-week, double-blind, placebo-controlled study of the efficacy and safety of eprosartan in patients with essential hypertension. J. Hypertens. (1997) 15 (Suppl. 4):S116.
   Google Scholar
• LACOURCIERE Y, PORIER L: Tasosartan: a once-a-day angiotensin II (All) receptor antagonist with a documented dose-response. J. Hypertens. (1997) 15 (Suppl. 4) :S116.
   Google Scholar
• PITT B, SEGAL R, MARTINEZ FA: Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• VAL-HEFT to investigate valsartan in treatment of congestive heart failure. Can. J. Cardiol. (1997) 13:971–972.
   Web of Science ®Google Scholar
• YOUNG JB: Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials. Cardiovasc. Drugs Ther. (1995) 9:89–102
   PubMed Web of Science ®Google Scholar
• TEERLINK JR: Neurohumoral mechanisms in heart failure: a central role for the renin-angiotensin system. J. Cardiovasc. Pharmacol. (1996) 27 (Suppl. 2):S1–S8.
   PubMed Web of Science ®Google Scholar
• Candesartan mortality concerns stop trial. Scrip (12 November 1997).
   Google Scholar
• ODDOU-STOCK P, GATLIN M, KOBI P e al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension. Am. J. Hypertens. (1997) 10:84A (H29).
   Google Scholar
• ANDERSSON OK, NELDAM S: A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J. Human Hypertens. (1997) 11 (Suppl. 2):S63–S64.
   PubMed Web of Science ®Google Scholar
• MCINTYRE M, CAFFE SE, MICHALAK RA e al. Losartan, an orally active angiotensin (ATi) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol. Ther. (1997) 74:181–194.
   PubMed Web of Science ®Google Scholar
• WEXLER RR, GREENLEE WJ, IRVIN JD e al. Non-peptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J. Med. Chem. (1996) 39:625–656.
   PubMed Web of Science ®Google Scholar
• KIVLIGHN SD, ZINGARO GJ, GABEL RA TP e al. In vivo pharmacology of L-163,017: a potent nonpeptide angiotensin II receptor antagonist with balanced affinity for ATi and AT2 receptors. Eur. J. Pharmacol. (1995) 294:439–450.
   PubMed Web of Science ®Google Scholar